Drug intelligence / Profile preview

BR5402C-1

Development stage: Unknown
Lead developer: Boryung
Modality: Small Molecules
Administration: Oral

Overview

BR5402C-1 is an investigational product designation used by Boryung Pharmaceutical Co., Ltd. in a Phase 2 clinical trial (NCT06821945) evaluating different olanzapine titration schedules in patients with schizophrenia. The active ingredient is olanzapine, an atypical antipsychotic that works by regulating dopamine and serotonin imbalances in the brain. This specific designation represents one of several investigational dosing schedules or formulations being compared in a randomized, double-blind trial to evaluate gradual versus conventional titration approaches. Olanzapine is the generic name for Zyprexa, for which Boryung acquired the Korean rights from Eli Lilly in 2021.

Other names: olanzapine

Targets

DRD2 (Dopamine D2 Receptor)HTR2A (Serotonin receptor 5-HT2A)

Beyond the preview

Go deeper on BR5402C-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR5402C-1.

Explore the full profile